Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
53 hedge funds and large institutions have $58M invested in Concert Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 24 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 52 → 53 (+1)
2% more capital invested
Capital invested by funds: $57.1M → $58M (+$882K)
4% less call options, than puts
Call options by funds: $54K | Put options by funds: $56K
71% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.2M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$202K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$75.1K |
| 4 |
Jane Street
New York
|
+$52.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.07M |
| 2 |
Morgan Stanley
New York
|
-$668K |
| 3 |
Renaissance Technologies
New York
|
-$474K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$349K |
| 5 |
Millennium Management
New York
|
-$329K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $364 | -$77.4K | -24,426 | -100% |
|
|
IA
52
IndexIQ Advisors
New York
| – | -$267K | -84,631 | Closed |
|
53
Marshall Wace
London,
United Kingdom
| – | -$143K | -45,383 | Closed |
|
54
Truist Financial
Charlotte,
North Carolina
| – | -$63K | -20,000 | Closed |
|
|
AG
55
Algert Global
San Francisco,
California
| – | -$61K | -19,300 | Closed |
|
|
XT
56
XTX Topco
George Town,
Cayman Islands
| – | -$45K | -14,305 | Closed |
|
|
CSS
57
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$39K | -12,254 | Closed |
|
|
TSS
58
Two Sigma Securities
New York
| – | -$34K | -10,921 | Closed |
|
|
DTL
59
Dynamic Technology Lab
Singapore
| – | -$33K | -10,536 | Closed |
|
CNCE Hedge Fund Activity: Q1 2022 in Review
53 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2022, worth a combined $58M — up 1.5% from $57.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CNCE positions and 8 closed out — a net gain of 1 holder — while 7 added to existing stakes and 24 trimmed.
The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $1.2M. The largest seller was Vanguard Group, cutting an estimated $1.07M.
- 53 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2022, up from 52 in Q4 2021.
- Funds reported $58M of Concert Pharmaceuticals, Inc. stock for Q1 2022, up 1.5% quarter-over-quarter.
- 9 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2022 and 8 closed out, a net change of +1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2022 was Parkman Healthcare Partners, an estimated $1.2M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2022 was Vanguard Group, an estimated $1.07M sold.
Based on aggregated 13F filings for Q1 2022.